San Diego-based biotechnology company Pfenex Inc. has made significant strides in the development of biosimilar therapeutics. With a focus on ophthalmology, the firm's lead product candidate PF582 is a biosimilar to Lucentis that is currently in Phase Ib/IIa clinical trials for patients with wet age-related macular degeneration. The company is poised for success as it continues to develop treatments for a wide range of health concerns.